Publication | Closed Access

Serotype-specific effectiveness of 23-valent pneumococcal polysaccharide vaccine against pneumococcal pneumonia in adults aged 65 years or older: a multicentre, prospective, test-negative design study

VaccinologyVaccine SafetyVaccinationTest-negative Design StudyVaccine TestingRespiratory InfectionPneumococcal PneumoniaVaccine EfficacyInfection ControlMedicineSerotype-specific EffectivenessEpidemiology